ArticleCureus2026
Central Serous Chorioretinopathy in Kidney Transplant Recipients: A Report of Three Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by subretinal fluid accumulation in the macular region and is commonly associated with psychological stress and prolonged corticosteroid exposure. In kidney transplant recipients, CSCR represents an underrecognized complication related to immunosuppressive therapy. We report three cases of CSCR occurring in male kidney transplant recipients receiving corticosteroid-based immunosuppression. Clinical presentation was dominated by decreased visual acuity and blurred vision. Diagnosis was established by ophthalmologic examination and fluorescein angiography in all cases, with optical coherence tomography (OCT) findings available in two patients. Two patients, aged 35 and 37 years, developed CSCR within weeks following transplantation while receiving corticosteroids, mycophenolate mofetil, and calcineurin inhibitors. In the third case, a 65-year-old diabetic patient was diagnosed incidentally during routine ophthalmologic follow-up. Gradual tapering of corticosteroids resulted in favorable clinical and visual outcomes in all patients. CSCR in kidney transplant recipients is mainly associated with prolonged corticosteroid therapy and may occur from the early post-transplant period to several years after transplantation. Early diagnosis and close collaboration between nephrologists and ophthalmologists are essential to optimize management, prevent visual complications, and preserve patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.